Adaptimmune Therapeutics (NASDAQ:ADAP) Receives "Neutral" Rating from HC Wainwright

Key Points

• HC Wainwright has dropped Adaptimmune Therapeutics (NASDAQ:ADAP) from a "buy" to a "neutral" rating, reflecting a shift in analysts' outlook.
• Barclays reduced their target price for the stock significantly from $1.00 to $0.46, indicating growing caution among investors.
• Adaptimmune's recent quarterly earnings report showed a negative EPS of ($0.18) but beat revenue expectations by generating $7.29 million.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Marketbeat reports. HC Wainwright also issued estimates for Adaptimmune Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.42) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Jones Trading cut shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Wall Street Zen initiated coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 16th. They issued a "buy" rating for the company. Mizuho cut shares of Adaptimmune Therapeutics from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $1.50 to $0.50 in a research report on Thursday, June 26th. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 14th. Finally, Barclays dropped their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $1.35.

Adaptimmune Therapeutics Stock Performance

Shares of Adaptimmune Therapeutics stock traded down $0.00 during trading on Tuesday, reaching $0.08. The company's stock had a trading volume of 83,226,336 shares, compared to its average volume of 14,165,194. The business's 50-day moving average price is $0.25 and its 200-day moving average price is $0.35. The firm has a market cap of $21.18 million, a PE ratio of -0.30 and a beta of 2.18. Adaptimmune Therapeutics has a 52 week low of $0.08 and a 52 week high of $1.35. The company has a quick ratio of 1.79, a current ratio of 2.02 and a debt-to-equity ratio of 4.24.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18). The company had revenue of $7.29 million during the quarter, compared to analysts' expectations of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. Equities analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ADAP. Virtu Financial LLC increased its position in Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 21,688 shares during the period. LPL Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 106.5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 94,623 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 28,526 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock valued at $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its stake in Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company's stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.